Nicotinamide adenine dinucleotide, better known as NAD+, is one of the most heavily studied molecules in aging biology. It sits at the center of cellular energy metabolism, DNA repair, and a family of proteins called sirtuins that many researchers consider central to how organisms age. Over the past two decades, NAD+ has moved from a niche biochemistry topic to a major focus of longevity research, with labs around the world using preclinical models to understand exactly how its decline relates to the aging process — and whether restoring it can change outcomes.
This article summarizes what the research literature says about NAD+, without making any claims about human supplementation, treatment, or outcomes. It’s written for people following the aging and longevity research space, not as guidance for personal use.
What NAD+ Does in the Cell
NAD+ is a coenzyme present in every living cell, and it plays a dual role that makes it unusually important to metabolic research. First, it acts as an electron carrier in redox reactions, cycling between its oxidized form (NAD+) and reduced form (NADH) to shuttle electrons through glycolysis, the citric acid cycle, and oxidative phosphorylation — the core pathways cells use to generate ATP, the molecule that powers nearly all cellular work. Without adequate NAD+, mitochondria cannot efficiently convert nutrients into usable energy.
Second, and equally important for aging research, NAD+ is consumed as a substrate — not just a carrier — by several enzyme families. Sirtuins, a class of NAD+-dependent deacetylases, use NAD+ to remove acetyl groups from proteins involved in metabolic regulation, stress resistance, and gene expression. Poly(ADP-ribose) polymerases (PARPs), which respond to DNA damage, also consume NAD+ as part of the DNA repair process. Because both of these enzyme families draw from the same NAD+ pool, cellular demand for NAD+ is directly tied to how much repair and regulatory work a cell is doing.
Why NAD+ Levels Decline With Age
A consistent finding across preclinical studies is that NAD+ levels fall over the course of an organism’s lifespan. Research points to several converging mechanisms behind this decline. One is reduced activity of NAMPT, the rate-limiting enzyme in the primary pathway that regenerates NAD+ from its breakdown products — as NAMPT activity drops, so does the cell’s capacity to replenish its NAD+ supply. A second contributor is increased NAD+ consumption by PARPs, driven by the accumulation of DNA damage that naturally occurs with age; the more DNA repair a cell has to perform, the more NAD+ gets diverted away from other uses. Chronic low-grade inflammation, sometimes referred to in the literature as “inflammaging,” has also been studied as a driver of NAD+ depletion through enzymes like CD38, which degrades NAD+ and its precursors.
The downstream consequence, as described in aging research, is a kind of resource squeeze: less NAD+ available means less sirtuin activity, which in turn is associated with impaired mitochondrial quality control, reduced stress resilience, and disrupted communication between the nucleus and mitochondria. This has led some researchers to describe declining NAD+ availability as a plausible contributor to several age-related functional declines observed in cellular and animal models.
Sirtuins, Mitochondrial Function, and DNA Repair Pathways
Sirtuins are frequently described in the literature as “metabolic sensors” because their activity rises and falls with the cell’s NAD+/NADH ratio, effectively linking a cell’s energy state to gene expression and stress response. In preclinical models, sirtuin activity — often studied indirectly by restoring NAD+ levels — has been associated with improved mitochondrial biogenesis, activation of mitochondrial unfolded protein response pathways, and modulation of FOXO transcription factors involved in stress resistance and metabolic regulation.
The DNA repair side of the NAD+ story centers on PARP enzymes, which are essential for repairing single-strand DNA breaks. Because PARPs consume NAD+ during this repair process, the accumulation of DNA damage over a lifetime creates ongoing competition for a limited NAD+ pool. Researchers studying this pathway have proposed that this competition between DNA repair and sirtuin-driven regulatory processes may partly explain why cellular resilience appears to decline with age across model systems, from yeast and C. elegans to rodents.
NAD+ Precursors in Preclinical and Early Clinical Research
Because NAD+ itself is not efficiently taken up by cells, most research on restoring NAD+ levels has focused on precursor molecules — most notably nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR), both of which feed into NAD+ biosynthesis pathways. In preclinical models, supplementation with these precursors has been shown to raise tissue NAD+ levels and has been studied in the context of mitochondrial function, muscle performance, metabolic health, cardiovascular markers, and neurodegenerative disease models.
It’s worth noting that translating these preclinical findings to human outcomes has proven more complicated. Early human trials have generally confirmed that NR and NMN supplementation can raise blood NAD+ levels, but measurable improvements in functional outcomes like cardiovascular health have been inconsistent across studies. This gap between preclinical promise and clinical translation is an active and openly discussed area of ongoing research, and it’s a reminder that cellular and animal model findings don’t automatically generalize to whole-organism human physiology.
Where the Research Stands
NAD+ remains one of the more compelling threads in aging biology precisely because it connects several hallmark processes — energy metabolism, DNA repair, and epigenetic regulation via sirtuins — through a single, measurable molecule. Preclinical models have provided a fairly detailed mechanistic picture of how NAD+ decline and restoration affect cellular function, even as questions about dosing, tissue-specific effects, and long-term human outcomes remain open for future study.
Disclaimer: This article is provided for educational and research-context purposes only. It summarizes published scientific literature and is not medical advice, and it does not recommend or endorse the use of any compound for human or veterinary treatment, diagnosis, prevention, or supplementation. NAD+ and related compounds sold by Great Lakes Peptide Co. are intended strictly for laboratory research use by qualified researchers and institutions — not for human or veterinary use, consumption, or application. Anyone with questions about their own health should consult a licensed physician.